VYNE Therapeutics (VYNE) Retained Earnings (2016 - 2025)
VYNE Therapeutics (VYNE) has disclosed Retained Earnings for 10 consecutive years, with $2000.0 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings rose 100.0% year-over-year to $2000.0, compared with a TTM value of $2000.0 through Dec 2025, up 100.0%, and an annual FY2025 reading of $2000.0, up 100.0% over the prior year.
- Retained Earnings was $2000.0 for Q4 2025 at VYNE Therapeutics, up from -$745.5 million in the prior quarter.
- Across five years, Retained Earnings topped out at $2000.0 in Q4 2025 and bottomed at -$745.5 million in Q2 2025.
- Average Retained Earnings over 5 years is -$597.1 million, with a median of -$660.7 million recorded in 2022.
- Peak annual rise in Retained Earnings hit 100.0% in 2025, while the deepest fall reached 1285306.9% in 2025.
- Year by year, Retained Earnings stood at -$639.5 million in 2021, then fell by 2.08% to -$652.8 million in 2022, then decreased by 5.9% to -$691.3 million in 2023, then fell by 5.76% to -$731.2 million in 2024, then skyrocketed by 100.0% to $2000.0 in 2025.
- Business Quant data shows Retained Earnings for VYNE at $2000.0 in Q4 2025, -$745.5 million in Q2 2025, and -$739.8 million in Q1 2025.